| Literature DB >> 30979199 |
João Augusto Oshiro Junior1, Marina Paiva Abuçafy2, Eloísa Berbel Manaia3, Bruna Lallo da Silva4, Bruna Galdorfini Chiari-Andréo5,6, Leila Aparecida Chiavacci7.
Abstract
This is a review of hybrid materials based on silica as an inorganic phase used as drug delivery systems (Entities:
Keywords: drug delivery systems; organic-inorganic materials; sol-gel process
Year: 2016 PMID: 30979199 PMCID: PMC6432574 DOI: 10.3390/polym8040091
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Figure 1Representation of (A) Class I; (B) Class II; and (C) Class III of organic-inorganic hybrid materials. The white symbols represent the inorganic phase and the black ones represent the organic phase (adapted from the study by Benvenutti et al., 2009 [33]).
Figure 2Number of publications which contains the terms “organic-inorganic” and “drug delivery” (ISI: Web of Science, accessed on 28 August 2015 [50]).
Figure 3Schema of stimuli-responsive organic-inorganic materials for drug delivery systems (adapted from the study by Santilli et al., 2009 [60]).
Figure 4Bone defect repair using biomaterials: (a) the biomaterial releases bioactive molecules that interact with the bone cells; (b) it increases the quantity of bone tissue and occurs the degradation of the biomaterial, and finally; (c) occurs the regeneration of the tissue without presence of biomaterial.
Figure 5Molecules and biological interactions of ureasil-PEO and ureasil-PPO hybrid materials. Possible sites of bonding with the biological substrate and drugs are highlighted in the blue circles [64].
Figure 6Possible links between sites of hybrid material and molecules (I, II and III) [60].
Composition and time of release of drug to selected organic-inorganic systems.
| Organic-Inorganic System Composition | Drug | Time of Released of Drug | Comments | Reference |
|---|---|---|---|---|
| PVA/PNIPAAm | Rhodamine B | 16 h = ± 95% at 38 °C | Temperature influences in the release behavior | [ |
| BTEPAA | Doxorubicin | 48 h = ± 10% in pH ≤ 9 and | pH responsive systems | [ |
| Cs/MSM | Ibuprofen | 4 h = ± 20% in pH 7.4 and | pH responsive systems | [ |
| NAS/NAphMA/OEGMA/MSM | Rhodamine B | 4 h = ± 95% with 20 mM DDT | Fluorescence properties | [ |
| PEO/3-(isocyanatopropyl)-triethoxysilane/Magnetite | Sodium diclofenac | 4 h = ± 95% with the application magnetic and 80% without magnetic field (0.250 T, 220 kHz) | Stimulis with Magnetic field | [ |
| Pluronic/Tetraethyl orthosilicate/P2O5/H3PO4 | Alendronate | 4 h = 25 µg·m−2 to material without P2O5 and 87 µg·m−2 to material with P2O5 | Implantable systems | [ |
| PLGA/PS | Gentamicin | 24 h = 77% PLGA pure and 41% PLGA/PS. | Implantable Systems | [ |
| PEO/3-(isocyanatopropyl)-triethoxysilane/Chitosan | Pramoxine | 3 h = ± 100% without chitosan and 30% with 3% of chitosan | Film-forming systems | [ |
| Pluronic(127)/CPPs/Tetraethyl orthosilicateas | FITC/octaarginine | 5 days = 85% | New devices of DDS | [ |